Saint Joseph's Regional Medical Center
Saint Joseph's Regional Medical Center
Paterson, New Jersey, United States58 results ยท Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 | Recruiting | Phase 3 | 2026-10-09 | NCT05675410 | |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, acute biphenotypic leukemia, acute leukemia of ambiguous lineage, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Phase 2 | 2026-10-08 | NCT06317662 | |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, ganglioneuroblastoma, neoplasm, neuroblastoma, neuroepithelial neoplasm, nodular ganglioneuroblastoma, primitive neuroectodermal tumor | Recruiting | Phase 3 | 2026-10-08 | NCT06172296 | |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Phase 2 | 2026-10-08 | NCT06124157 | |
| A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis | Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, histiocytosis, interstitial lung disease, lung disorder, lymphatic system disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-10-08 | NCT05828069 | |
| A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, epithelial neoplasm, glioma, malignant glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 / Phase 2 | 2026-10-08 | NCT05099003 | |
| NCI COVID-19 in Cancer Patients, NCCAPS Study | COVID-19, Coronaviridae Infections, Infections, Neoplasm Metastasis, Neoplastic Processes, Nidovirales infectious disease, Orthocoronavirinae infectious disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, lung disorder, neoplasm, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Active, not recruiting | Not stated | 2026-10-07 | NCT04387656 | |
| MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, hereditary disease, hereditary neoplastic syndrome, inherited neurodegenerative disorder, neoplasm, nerve sheath neoplasm, nervous system disorder, neurocutaneous syndrome, neurodegenerative disease, neurofibroma, neurofibromatosis, neurofibromatosis type 1, neuromuscular disease, peripheral nervous system disorder, peripheral nervous system neoplasm, plexiform neurofibroma | Active, not recruiting | Phase 2 | 2026-10-06 | NCT03962543 | |
| Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | Ewing sarcoma, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, peripheral primitive neuroectodermal tumor of soft tissues, sarcoma | Active, not recruiting | Phase 3 | 2026-10-06 | NCT02306161 | |
| Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T-cell acute lymphoblastic leukemia, Tumor Virus Infections, acute biphenotypic leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mixed phenotype acute leukemia, neoplasm, viral infectious disease | Active, not recruiting | Phase 3 | 2026-10-05 | NCT03007147 | |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Early Stage HER2+ Breast Cancer | Recruiting | Phase 3 | 2026-10-02 | NCT06876714 | |
| Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, ureter cancer, ureteral disorder, urethra neoplasm, urethral disorder, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT05092958 | |
| Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma | primary mediastinal large B-cell lymphoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT04759586 | |
| A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia | Abnormalities, Multiple, B-cell neoplasm, Burkitt lymphoma, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Virus Infections, Down syndrome, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Neurobehavioral Manifestations, Neurologic Manifestations, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Tumor Virus Infections, chromosomal disorder, hematologic disorder, hereditary disease, immune system disorder, immunoproliferative disorder, intellectual disability, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, nervous system disorder, viral infectious disease | Active, not recruiting | Phase 3 | 2026-10-01 | NCT03914625 | |
| Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | Hemic and Lymphatic Diseases, Hodgkin's lymphoma, lymphocytic-histiocytic predominance, Hodgkins lymphoma, Neoplasms by Histologic Type, classic Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-10-01 | NCT03907488 | |
| Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Tumor Virus Infections, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Active, not recruiting | Phase 2 | 2026-10-01 | NCT02981628 | |
| Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma | Myosarcoma, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Rhabdomyosarcoma, Embryonal, alveolar rhabdomyosarcoma, botryoid rhabdomyosarcoma, myomatous neoplasm, neoplasm, rhabdomyosarcoma, sarcoma, spindle cell rhabdomyosarcoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT02567435 | |
| Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma | classic Hodgkin lymphoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT02166463 | |
| Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | Neoplasms by Histologic Type, Neoplasms, Ductal, Lobular, and Medullary, adenocarcinoma, breast carcinoma in situ, carcinoma, ductal breast carcinoma in situ, epithelial neoplasm, in situ carcinoma, invasive breast carcinoma, neoplasm, synchronous bilateral breast carcinoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT01272037 | |
| Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, light chain deposition disease, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT01169337 | |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | breast adenocarcinoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT00433511 | |
| Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT00310180 | |
| A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | Female Urogenital Diseases and Pregnancy Complications, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Pregnancy Complications, Neoplastic, Urogenital Diseases, adenocarcinoma, carcinoma, central nervous system nongerminomatous germ cell tumor, choriocarcinoma, embryonal carcinoma, epithelial neoplasm, malignant teratoma, mixed germ cell tumor, neoplasm, pineal region immature teratoma, pineal region yolk sac tumor, pregnancy disorder, teratoma, trophoblastic neoplasm | Recruiting | Phase 2 | 2026-09-23 | NCT04684368 | |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2026-09-17 | NCT04293562 | |
| Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial | invasive breast carcinoma | Active, not recruiting | Phase 2 | 2026-09-14 | NCT05710328 |